ESSA Pharma IncNASDAQ EPIX Stock Report

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 50 full-time employees. The company went IPO on 2021-02-22. The firm is focused on developing therapies for the treatment of prostate cancer. The firm's lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.